It’s not just for diabetes anymore
GLP-1 receptor agonists [semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)] are proving transformational for type II diabetes patients in particular and for obese individuals in general. Now, it appears they have benefits in cancer patients. “Use of GLP-1 receptor agonists in patients with four solid tumor types was significantly associated with lower rates of progression to metastatic disease over a 5-year period, a propensity score-matched analysis found. “In patients with stage I-III colorectal, liver, breast, or lung cancers, those who started a GLP-1 drug after their cancer diagnosis had a 31% to 50% lower risk of progression to stage IV disease compared with patients who initiated another class of antidiabetic drug, DPP-4 inhibitors, reported Mark David Orland, MD, of the Cleveland Clinic Taussig Cancer Institute.” *snip* “Initially approved for type 2 diabetes and obesity, GLP-1 drugs now carry indications in cardiovascular disease , chronic kidney di...